Pay in 4 interest-free payments of $8.75 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
116(22):4560-8
75% of total content with 10 μM 22 vs 8
Nakahara T
3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy
Treatment with RS-1 promoted significant antitumor responses in a mouse model
ESI-09 - CAS# 263707-16-0 size:2mg solid 116(22):4560-8ESI 09, CAS No. 263707 16 0, is a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC mediated Rap1 activation and Akt phosphorylation, as well as EPAC mediated insulin secretion in pancreatic cells. EPAC1 plays an important role in pancreatic cancer cell migration and invasion, and thus represents a potential target for developing novel therapeutic strategies for pancreatic cancer. Product